BioVie Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
BioVie Inc. (BIVI) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $59.41 thousand as of 2026-06-30, per its 10-K filed 2026-08-13.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-08-13
- 2026-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $59.41K.
- 2026-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $70.25K.
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $81.83K.
- 2025-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $94.08K.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2026-06-30 | $59.41K 10-K · filed 2026-08-13 |
| 2026-03-31 | $70.25K S-1/A · filed 2026-08-06 |
| 2025-12-31 | $81.83K 10-Q · filed 2026-02-06 |
| 2025-09-30 | $94.08K 10-Q · filed 2025-11-10 |
| 2025-06-30 | $106.99K S-1/A · filed 2026-08-06 |
| 2025-03-31 | $120.53K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $134.66K 10-Q · filed 2025-02-11 |
| 2024-09-30 | $149.69K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $164.56K 10-K · filed 2024-09-30 |
| 2023-06-30 | $9.38K 10-K · filed 2023-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |